BioAge Labs

The BioAge podcast, Translating Aging, features the people & companies advancing the science of human longevity and discovering drugs to extend healthspan. Our newest episode just dropped!

Excited to share our new preprint on our research providing detailed structural insights into BioAge’s novel class of brain-penetrant NLRP3 inhibitors, targeting a core driver of metabolic aging. In this study, we identified a new binding pocket on NLRP3 and demonstrated how it can be exploited to create highly potent, orally available inhibitors with a differentiated mechanism of action. Read the manuscript: https://lnkd.in/geKWYQCb Key findings: • Novel binding site: Our compounds bind to a previously undiscovered site on NLRP3, distinct from previously known inhibitors  • Unique mechanism of action: Represents a new approach to precise modulation of inflammasome activity • Blueprint for optimization: Structural insights provide a roadmap for designing next-generation NLRP3 therapeutics with enhanced properties NLRP3 is a key regulator of age-related chronic inflammation that drives multiple diseases and disrupts appetite control in obesity. BioAge is developing a member of this family of NLRP3 inhibitors, the potent, orally available, brain-penetrant small molecule BGE-102, for obesity. BGE-102 has demonstrated significant weight loss in preclinical obesity models, both as monotherapy and in combination with GLP-1 receptor agonists. The compound has completed IND-enabling studies, and Phase 1 single-ascending-dose (SAD) data are expected by year-end. Learn more about our NLRP3 inhibitors for obesity: https://lnkd.in/gZPvi2mW Congratulations to our longtime collaborators, led by the research group of Dr. Matthias Geyer at the University of Bonn, and BioAge’s exceptional scientific team, on this important advance!

At Discovery & Development Europe 2025 in Basel this week, our VP-Data Science Naisha S., PhD, showcased how human aging data can transform drug target discovery. In her talk "Targeting aging biology: exercise induced pathways for the treatment of neurodegenerative disease," Dr. Shah shared BioAge's efforts to identify therapeutic targets at the intersection of exercise and healthy aging. Since exercise remains the gold standard intervention for extending healthy lifespan and preventing diseases of aging, understanding its molecular mechanisms can reveal novel pathways for treating age-related and metabolic diseases. Naisha highlighted how our platform has already uncovered pathways like apelin signaling that may mediate exercise's neuroprotective effects. During a fireside chat entitled "Impact Of AI & Big Data In Drug Discovery & Development," Naisha further expanded on BioAge's unique longitudinal human aging datasets and our discovery collaborations with Novartis and the HUNT Biobank in Norway. She was joined by Ian Roberts of Healx in a conversation moderated by Mirko Bischofberger of Science Studios. Thanks to Ian and Mirko for a fascinating conversation!

Proud to share that BioAge presented some of our compelling new preclinical data on APJ agonism at the American Diabetes Association's 85th Scientific Sessions this week. BioAge is advancing next-generation APJ agonists to translate this promising biology into new therapies for obesity and its major comorbidities. Key benefits of APJ agonism in models of diabetic obesity and heart failure: • Enhanced glycemic control in diabetic obesity — Our CMO Paul Rubin, MD gave a talk on our data showing that APJ agonist treatment improved glycemic control and weight loss in diabetic obesity models, with further enhancement when combined with incretins. • Cardioprotective effects in HFpEF — Senior Scientist Shijun Yan, PhD, MBA, presented a poster demonstrating that APJ agonism reduced cardiac hypertrophy in heart failure models. Benefits were additive with the effects of incretins in these studies as well. Read the full update here:  ➡️ https://lnkd.in/gh8h5idC Many thanks to the organizers of #ADA2025 for an amazing, educational meeting—and giving us the opportunity to share our science with the global metabolic disease research community! 📸: 1) The BioAge team at the poster! Pictured: Shijun Yan, Paul Rubin, and study co-authors Yan Wang, PhD (SVP-Translational Biology) and Claudia Portillo (Senior Research Associate) 2) Catching up with our longtime collaborators Christine Kusminski, PhD and Philipp Scherer, PhD from UT-Southwestern Medical Center.  3) Paul Rubin at his talk, showing data demonstrating that apelin agonism slows weight gain in an obesity model.

The future of drug discovery is rooted in human biology—starting with preclinical human models that boost translational success. At #BIO2025, BioAge CEO Kristen Fortney joined the panel “Replacing Guesswork with Data: How Preclinical Human Models Are Driving More Predictive Drug Discovery” to share how BioAge mines 50+ years of human aging data to uncover promising drug targets. Thanks to Jarod Rutledge from Starbloom Capital for expertly moderating, and to Ashley Zehnder from Fauna Bio, Andrei Georgescu, Ph.D. from Vivodyne, and Wyatt McDonnell from Infinimmune for sharing their innovative approaches to human-centric discovery. Read about how we're expanding BioAge’s discovery platform with new longitudinal human aging data: https://lnkd.in/gWruMqn7

Highlights from the fascinating panel discussion "Weight Loss for Longevity? How Metabolic Drugs are Disrupting Chronic Disease and Improving Healthspan" at #BIO2025 yesterday... "Not even a decade ago, people thought, 'Obesity will never be a huge indication - no one's going to reimburse for prevention,'" noted BioAge CEO Kristen Fortney during the panel. "Now, those of us in the longevity field see that people are paying for prevention. It will be the biggest market ever in biotech—full stop. And that is making people think seriously about prevention in other areas." The conversation went far beyond weight loss numbers to explore the real end game: durable health outcomes that address the root causes of metabolic dysfunction. Key themes included  • the promise of complementary mechanisms that target energy expenditure rather than just appetite suppression, • the critical need for muscle preservation during weight loss, and  • precision approaches that recognize we're not all obese for the same reasons. Many thanks to moderator Mia de Graaf from Business Insider for facilitating such a thoughtful discussion, and to fellow panelists Maha Radhakrishnan from Sofinnova Investments , Gregory Wiederrecht PhD CLP from RBC, Ashley Zehnder from Fauna Bio, and Hanadie Yousef from Juvena Therapeutics. Their collective expertise across investment, clinical development, and platform science made for a truly enriching conversation. Looking forward to the continued evolution of this field as we work to transform how we treat obesity and extend healthy lifespan!

📸 At Founders Longevity Forum in London last week, BioAge COO and co-founder Eric Morgen, MD joined an expert panel to explore emerging therapies that target the fundamental drivers of aging. At the panel, Eric shared insights about how advances in aging biology research are translating into potential medical breakthroughs. He was joined by Alexandra Sharon Bause, PhD from Apollo Health Ventures and Reason from Repair Biotechnologies, in a conversation moderated by Todd White of The Thalion Initiative. At BioAge, we're advancing aging target discovery through our unique discovery platform built on over 50 years of longitudinal human aging data, which helps us discover and develop treatments that could significantly impact how we approach metabolic health as we age. The growing recognition of aging biology as a therapeutic frontier reflects the immense potential to transform medicine – moving from reactive treatment to novel medicines that address root causes rather than just managing symptoms. Founders Longevity Forum, organized by Founders Forum Group and Longevity.Technology, brings together leading founders, CEOs, VCs, and thought leaders to explore and invest in groundbreaking longevity innovations.

"It's like building a roadmap of human aging biology that can show us exactly where and when to intervene." — BioAge COO & co-founder Eric Morgen, MD, on the power of large-scale profiling of longitudinal aging data to yield new therapeutic targets. BioAge recently announced an initiative to profile over 17,000 samples from Norway's HUNT Biobank, tracking molecular changes across decades of adult lifespan. Learn more in this piece by Danny Sullivan in Longevity.Technology: ➡️ https://lnkd.in/eM4NYHTS

The tremendous success of GLP-1/GIP receptor agonists is rewriting the playbook for metabolic diseases. Today at #BIO2025, BioAge CEO Kristen Fortney will participate in an expert panel to discuss how the rapidly evolving therapeutic landscape has opened the door for next-generation therapies that tackle the root causes of chronic diseases — including aging itself. Joining Kristen will be an exceptional group of leaders spanning biotechnology innovation and life sciences investment: Ashley Zehnder (Fauna Bio), Gregory Wiederrecht PhD CLP (Royal Bank of Canada), Hanadie Yousef (Juvena Therapeutics), and Maha Radhakrishnan (Sofinnova Investments) — in a conversation moderated by Mia de Graaf from Business Insider. We're looking forward to a thought-provoking discussion about the future of metabolic medicine—and the therapeutic potential that emerges when we view chronic diseases through the lens of aging biology. "Weight Loss for Longevity? How Metabolic Drugs are Disrupting Chronic Disease and Improving Healthspan" Wednesday, June 18th, 9:00 AM 

BioAge is excited to kick off a new initiative with Norway’s HUNT Biobank - one of Europe's most comprehensive population health studies - to map how molecular changes across decades shape healthy aging. https://lnkd.in/g2-5YSDK Through our collaboration with Norwegian diagnostics company Age Labs AS, we will generate molecular profiles of samples from thousands of HUNT participants tracked across decades of life, deepening our understanding of what keeps some people resilient against chronic diseases as they age. Insights from the collaboration will feed directly into BioAge’s discovery platform, which uses one of the world's most extensive collections of longitudinal human aging data to identify novel therapeutic targets that address the root biology of aging. We look forward to the discoveries ahead! Learn more about the collaboration: https://lnkd.in/gDJzpNEk